1. Introduction {#sec0005}
===============

Gastric cancer with paraaortic lymph node (PAN) metastasis is classified as distant metastasis and as Stage IV under the 7th Union for International Cancer Control (UICC^7th^) guidelines. Furthermore, surgery for Stage IV gastric cancer is not indicated according to the Japanese gastric cancer treatment guidelines [@bib0005]. The prognosis for stage IV gastric cancer is extremely poor [@bib0010] and currently, there are no evidence-based preoperative chemotherapy regimens available. Here, we report a patient with advanced gastric cancer with PAN metastasis who showed pathologically complete response and favorable outcomes after S-1/CDDP chemotherapy.

2. Case presentation {#sec0010}
====================

A 62-year-old woman visited her previous doctor complaining of epigastric discomfort. She was referred to our hospital for a complete examination. She had an unremarkable medical history without anorexia and loss of weight. Her height was 156 cm, weight was 54 kg, and body surface area was 1.52 m^2^. We measured levels of carcinoembryonic antigen (15.4 ng/mL) and carbohydrate antigen 19--9 (normal), which are tumor markers. Esophagogastroduodenoscopy (EGD) indicated the presence of a Borrmann type 3 tumor in the lesser curvature of the stomach ([Fig. 1](#fig0005){ref-type="fig"}A), and histological biopsy specimens showed poorly differentiated adenocarcinoma. Abdominal computed tomography (CT) demonstrated enhanced and thickened gastric wall with multiple metastatic regional lymph nodes. Lymph nodes along the celiac artery and the lesser curvature were remarkably swollen (i.e., bulky N2) ([Fig. 2](#fig0010){ref-type="fig"}A). Metastasis to PAN (No. 16a2) was also observed ([Fig. 2](#fig0010){ref-type="fig"}B). We diagnosed the patient with unresectable gastric cancer (M, Less, Borrman type 3, cT4a, cN3a, cH0, cP0, cM1, cStage IV according to UICC^7th^) and attempted to perform treatment with S-1 (tegafur, gimestat, and otastat potassium) with CDDP (cisplatin) chemotherapy. We anticipated that the tumor would be downstaged as a result of the chemotherapy. S-1 (120 mg/body/day) was given orally twice daily for the first 3 weeks of a 4-week course. CDDP was given as an intravenous infusion of 90 mg/body/day on day 8 of each course. She completed 6 courses of this regimen without severe adverse effects. EGD after chemotherapy demonstrated that the gastric lesion was scarred ([Fig. 1](#fig0005){ref-type="fig"}B). Additionally, abdominal CT revealed a reduction in the size of the regional lymph nodes ([Fig. 2](#fig0010){ref-type="fig"}C), especially the PAN ([Fig. 2](#fig0010){ref-type="fig"}D); this was considered an indication for surgery. She underwent surgery 55 days after the administration of the last dose of chemotherapy. We performed total gastrectomy and D2 lymphadenectomy as well as paraaortic lymph node dissection with Roux-en-Y reconstruction. The surgery lasted for 341 min and the total blood loss was 734 ml. No macroscopic metastases were found in the liver and peritoneum, including a negative result of peritoneal washing cytology (CY0). Macroscopically, the gastric lesion in the resected specimen was scarred ([Fig. 3](#fig0015){ref-type="fig"}). Histopathology, no cancerous cells were detected in the scarred region of the stomach. The number of dissected lymph nodes was 47, and there were no metastatic lymph nodes, including PANs. The therapeutic effect of the chemotherapy was Grade 3.Fig. 1(A) EGD before chemotherapy revealed Borrmann type 3 cancer in the lesser curvature of the stomach. Histological examination of the biopsy showed poorly differentiated adenocarcinoma. (B) EGD after chemotherapy showed a scar-like flat lesion in the lesser curvature of the stomach. Cancer cells were not found in the biopsy specimen.Fig. 1Fig. 2Abdominal enhanced CT before chemotherapy demonstrated (A) bulky lymph nodes along the celiac artery (No.9 \[33 mm\]) and the lesser curvature (No.3 \[42 mm\]). (B) Paraaortic lymph nodes (No.16a2) were swollen (27 mm). CT after chemotherapy revealed (C) that No.9 disappeared and that No.3 shrunk. (D) No.16a2 was also reduced in size.Fig. 2Fig. 3Macroscopic findings of the resected specimen revealed a scar-like lesion in the lesser curvature of the stomach. One tick mark = one mm.Fig. 3

The postoperative course was uneventful, and the patient was discharged from our hospital on postoperative day 14. We simply followed up her without adjuvant chemotherapy, and she remained disease-free for 5 years after surgery.

3. Discussions {#sec0015}
==============

Stage IV gastric cancers have an unfavorable prognosis. The Japanese gastric cancer association reported that the 5-year survival rate in patients with gastric cancer are as follows: Stage IA, 92.2%; Stage IB, 85.3%; Stage II, 72.1%; Stage IIIA, 52.8%; Stage IIIB, 31.0%; and Stage IV, 14.9% [@bib0010]. Gastric cancers with PAN metastasis also have an extremely unfavorable prognosis and poor curability, with the 5-year survival rate being approximately 5% [@bib0015], [@bib0020].

There are currently no evidence-based preoperative chemotherapy regimens for Stage IV gastric cancer. The S-1/CDDP is one of the first line chemotherapy regimens for Stage IV gastric cancer in Japan. In a phase II study using this regimen in patients with metastatic gastric cancer, a high response rate of 76.0% and an acceptable side-effect rate of 26.0% (Grades 3--4) were reported [@bib0025]. These results were confirmed in a phase III study (SPIRITS trial) for metastatic gastric cancer where S-1/CDDP showed a much higher response rate of 54.0% than S-1 monotherapy, which had a response rate of 31.1% [@bib0030]. Based on the SPIRITS trial, we decided the schedule and dose of S-1 (orally twice daily 120 mg/day for the first 21 days, calculated according to the patient's body surface area \>1.5 m^2^) and cisplatin (intravenous infusion of 60 mg/m^2^ on day 8 of each cycle).

A standard treatment for gastric cancer with paraaortic lymph node metastasis has yet to be determined. The Japan Clinical Oncology Group (JCOG) 0405 was a phase II clinical study of preoperative S-1/CDDP chemotherapy for gastric cancer with PANs and/or bulky lymph node enlargement but no other distant metastases [@bib0035]. This was followed by gastrectomy with extended lymph node dissection including PAN. Fifty-three patients were enrolled, and among the 51 who proved eligible, R0 resection was performed in 42 patients (82.4%). A subsequent analysis showed a good response rate of 64.7%, 3-year survival rate of 58.5% and 5-years survival rate of 52.7%. S-1/CDDP is possibly an effective regimen for preoperative chemotherapy in gastric cancer patients with PANs.

A PubMed search using key words, such as gastric cancer, PAN, S-1/CDDP, and pathological complete response (pCR), resulted in only 6 relevant well-documented cases ([Table 1](#tbl0005){ref-type="table"}) [@bib0040], [@bib0045], [@bib0050], [@bib0055], [@bib0060], [@bib0065]. The 7 cases consisted of 6 men and 1 woman, whose ages ranged from 59 to 67 years (mean 61.7 years). The histologic types of six-sevenths cases were poorly differentiated adenocarcinoma. The regimens of 4 cases were based on the SPIRITS trial. In all cases, the sizes of the PAN were less than 3 cm, and the PAN metastases were in No.16a2: lymph nodes between the celiac axis and lower border of the left renal vein [@bib0070]. There were no reports of a similar patient attaining a 5-year survival.Table 1Published cases of para-aortic lymph node metastasis with complete response to S-1/CDDP chemotherapy.Table 1No.AuthorYearAge/SexChemotherapyHistologic typePAN[a](#tblfn0005){ref-type="table-fn"} size (cm)PAN positionOperationAdjuvant chemotherapyOutcome1Sugiki^11)^200659/MS-1 100 mg \[days 1--28\]por3 × 1.5\#16a2 lateroDG + D1 + α--1Y aliveCDDP 10 mg \[day 1, 15\] 8 cycles2Shiraishi^12)^200759/MS-1 120 mg \[days 1--21\]por2\#16a2 interDG + D2--2Y3 M aliveCDDP 90 mg \[day 8\] 2 cycles+PAND[b](#tblfn0010){ref-type="table-fn"}3Fujisawa^13)^200760/MS-1 120 mg \[days 1--21\]por2 × 1.5\#16a2 interDG + D2--1Y aliveCDDP 75 mg \[day 8\] 2 cycles4Matono^14)^200867/MS-1 120 mg \[days 1--21\]tub2--\#16a2 interDG + D2S-1 120 mg/day2Y aliveCDDP 25 mg \[day 8\] 2 cycles\#16a2 latero+PAND4weeks, q2weeks, 1Y5Oshima^15)^201059/MS-1 120 mg \[days 1--21\]por2.5\#16a2 lateroDG + D2S-1 120 mg/day6 M aliveCDDP 93 mg \[day 8\] 3 cycles+PAND4weeks, q2weeks, 1Y6Kitayama^16)^201566/MS-1 120mg \[days 1--21\]por--\#16a2 lateroTG + D2S-1 120 mg/day2Y10 M aliveCDDP 90 mg \[day 8\] 3 cycle2weeks, q1week, 1Y7Our case201762/FS-1 120 mg \[days 1--21\]por2.7\#16a2 lateroTG + D2--5YCDDP 90 mg \[day 8\] 6 cycle+PAND[^1][^2]

In our case, we attempted treatment using combined preoperative S-1/CDDP chemotherapy with surgery. Consequently, pathological specimens showed no cancer cells, thereby indicating pCR. This case is rare and treatment resulted in a desirable outcome without adjuvant chemotherapy. It is possible that preoperative S1/CDDP with surgery might be a standard treatment strategy for gastric cancer with PANs.

4. Conclusions {#sec0020}
==============

We report herein a rare case of a patient with advanced gastric cancer with PAN metastases who achieved a 5-year survival after S-1/CDDP chemotherapy and surgery.
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[^1]: PAN: paraaortic lymph node.

[^2]: PAND: paraaortic lymph node dissection.
